Semaglutide Microdose

Microdose semaglutide refers to using semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, at a weekly dose below the lowest FDA-approved starting dose of 0.25 mg. In everyday practice, this most often means somewhere between 0.05 mg and 0.2 mg per week, though there is no consensus clinical definition and no randomized controlled trial has tested a true microdose as a primary endpoint (Cedars-Sinai, Hackensack Meridian Health, STAT News).

Microdosing sits below the FDA-approved starting dose. The term originates in patient and telehealth communities, not in regulatory guidance or peer-reviewed medicine. As Dr. Amanda Velazquez, obesity-medicine director at Cedars-Sinai, put it: "Microdosing is not a medical term. We don't have any evidence that low-dose, intermittent use of GLP-1s provides meaningful or sustained weight loss or broader health benefits" (Cedars-Sinai).

What the evidence does show is a clear dose-response relationship. In the STEP-1 trial, semaglutide 2.4 mg produced an average of 14.9% body-weight loss over 68 weeks; lower doses within the studied range (0.5 to 1.7 mg) produce proportionally smaller weight change (Wilding et al., NEJM 2021). No trial has tested weekly doses below 0.25 mg for weight loss, so any efficacy claims about true microdoses are extrapolations, not evidence.

Google's AI Overview and academic-medical-center commentary identify three main groups of patients who explore subtherapeutic semaglutide dosing. Each is a decision made in conversation with a licensed provider, not a self-titration.

1. Side-effect tolerance. Gastrointestinal adverse events (nausea, vomiting, constipation, diarrhea) scale with dose in the STEP program, and about 4.5% of patients discontinue for GI reasons on 2.4 mg semaglutide (Wilding et al., NEJM 2021). Some patients and providers use very slow titration to stay at a tolerable dose. A 2025 Diabetes Care commentary describes physicians using multidose pens for fractional micro-titration below the FDA-approved starting dose specifically for GI tolerability (Komé et al., 2025).
2. Weight maintenance after significant loss. The STEP-4 trial found that patients who switched from semaglutide 2.4 mg to placebo after 20 weeks regained approximately two-thirds of their prior weight loss over the next year, while those who stayed on 2.4 mg continued to lose (Rubino et al., JAMA 2021). Some patients explore a lower maintenance dose as a middle path, though STEP-4 tested continuation vs. full discontinuation, not a reduced-dose arm.
3. Metabolic and non-weight goals. Semaglutide's cardiovascular benefit in the SELECT trial (reduction in major adverse cardiovascular events) was demonstrated at 2.4 mg, not at microdoses (Lincoff et al., NEJM 2023). A 2025 preclinical bioRxiv preprint reported that low-dose semaglutide produced cardiac and hepatic benefits independent of weight loss in obese rats with HFpEF, but this is animal data and has not been replicated in humans (bioRxiv preprint, 2025).

Here is the honest state of published evidence on subtherapeutic semaglutide as of 2026:

• STEP-1 (semaglutide 2.4 mg, 68 weeks): mean weight change of −14.9% vs. −2.4% for placebo. Titration ran through 0.25, 0.5, 1.0, and 1.7 mg on the way to 2.4 mg; the trial did not report weight-loss outcomes for doses held at lower levels (NEJM 2021).
• STEP-4 (maintenance): after 20 weeks of titration to 2.4 mg, patients continuing on 2.4 mg lost an additional 7.9% of body weight over the next 48 weeks; patients switched to placebo regained about 6.9% (JAMA 2021).
• Komé et al., Diabetes Care 2025: commentary describing semaglutide multidose-pen fractional titration below the FDA-approved starting dose for GI tolerability, drug transitions, or cost. The authors explicitly note the practice is not endorsed by the manufacturer and lacks controlled-trial validation (PMC12964163).
• Wu, Cengiz, Lawley, Obesity 2025: case series and pharmacokinetic model suggesting that reduced-frequency dosing (biweekly instead of weekly) may preserve about 72% of weight-loss efficacy for maintenance. This is a frequency change, not a dose change, and is preliminary (PMC12210098).
• SELECT (semaglutide 2.4 mg, cardiovascular outcomes): 20% relative reduction in major adverse cardiovascular events over ~3.3 years, established at 2.4 mg, not at lower doses (NEJM 2023).
• FDA Wegovy label: approved dose escalation is 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks. The label does not describe or approve maintenance below 1.7 mg (FDA Wegovy label).

What the evidence does not show: No randomized trial has demonstrated meaningful weight loss, cardiovascular benefit, or metabolic benefit from weekly semaglutide doses below 0.25 mg. Any efficacy claim about true microdoses is extrapolation from the dose-response curve, not direct evidence.

Lower dose is not the same as lower risk. The FDA boxed warning and contraindications for semaglutide apply at any dose (FDA Wegovy label). Physicians at Cedars-Sinai and Hackensack Meridian have emphasized this repeatedly: microdose does not mean microrisk (Cedars-Sinai, Hackensack Meridian Health).

Contraindications that apply regardless of dose:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity to semaglutide
• Pregnancy or breastfeeding
• Active pancreatitis or a history of severe pancreatitis
• Severe gastroparesis

Adverse events that can occur at any dose: nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, acute kidney injury from dehydration, injection-site reactions, and rare cases of pancreatitis. Compounded semaglutide adds additional considerations because it is not FDA-approved as a finished drug product; safety depends on the compounding pharmacy following USP 797 sterile-compounding standards.

Provider oversight is the point. A licensed-provider evaluation reviews your medical history, current medications, laboratory values where appropriate, and goals before any protocol is set. Ongoing check-ins allow the provider to adjust or discontinue treatment if side effects, contraindications, or lack of benefit emerge. Microdose protocols should never be self-titrated based on internet dosing charts.

Through Madison Meds, compounded semaglutide is available in a range of protocols, including subtherapeutic ("microdose") formulations, after a licensed-provider evaluation by an independent network of US-licensed providers, with the medication dispensed by a US-licensed compounding pharmacy. Program pricing starts from $99 your first month and $149 per month thereafter for the microdose program, which reflects the smaller compounded dose.

Our licensed-provider network can discuss whether a lower-dose starter or maintenance protocol may be appropriate based on your individual health profile, prior GLP-1 experience, and goals. Because subtherapeutic dosing sits below the FDA-approved starting dose and lacks randomized trial support, providers will explain the trade-offs honestly: the appeal (slower onset, reduced GI side-effect reports, lower cost) and the limits (no efficacy guarantee, no proven cardiovascular benefit at microdose levels, ongoing safety monitoring still required).

Every prescription is written for an individual patient. Compounded semaglutide is not FDA-approved as a finished drug product, and Madison Meds does not represent it as equivalent to Wegovy or Ozempic. Outcomes are individual, and results vary from person to person.